XEN1101 for Seizures
(X-ACKT Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests XEN1101, a medication added to current treatments, in people with generalized epilepsy experiencing PGTCS who are already on 1-3 anti-seizure medications. The goal is to see if taking XEN1101 with an evening meal can help reduce seizure frequency.
Will I have to stop taking my current medications?
The trial requires that you stay on a stable dose of your current anti-seizure medications throughout the study.
Who Is on the Research Team?
Medical Director
Principal Investigator
Xenon Pharmaceuticals Inc.
Are You a Good Fit for This Trial?
This trial is for adults over 18 with a BMI ≤40 who have generalized epilepsy with tonic-clonic seizures despite trying at least two anti-seizure medications. They must be on a stable dose of their current meds and able to track their seizures. Excluded are those with recent severe seizure episodes, non-epileptic psychogenic seizures, or significant mental health issues.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive 12 weeks of blinded treatment with XEN1101 or placebo
Follow-up
Participants are monitored for safety and effectiveness after treatment
Open-label extension (optional)
Participants may opt into continuation of treatment with XEN1101 long-term
What Are the Treatments Tested in This Trial?
Interventions
- XEN1101
Find a Clinic Near You
Who Is Running the Clinical Trial?
Xenon Pharmaceuticals Inc.
Lead Sponsor
Worldwide Clinical Trials
Collaborator